Immunic reports Q1 2024 net loss $29.6M; cash extended into Q3 2025 on $240M private placement

IMMUNIC, INC.

2024-Q1 EPS reported -$0.30

Net loss $29.6M ($0.30/share) vs $25.3M ($0.58) in Q1 2023; R&D spend $18.7M, down 18% YoY.
Cash $97.3M at March 31, 2024; runway into Q3 2025 after $240M private placement ($80M initial tranche).
Phase 2 CALLIPER (progressive MS) top-line data expected April 2025; Phase 3 ENSURE readout Q2 2026 and H2 2026.
Received fourth US patent for vidofludimus calcium (composition of matter) protecting into 2041.
IMU-856 preparing for phase 2 in celiac disease after positive phase 1b data.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IMMUNIC, INC. reported financial results for the first quarter ended March 31, 2024.

Period: the first quarter ended March 31, 2024
Result: reported results

Exact text from the filing

On May 8, 2024, Immunic, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended March 31, 2024 and providing a corporate update

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

IMMUNIC, INC. filing history →

Source: SEC EDGAR

accession 0001193805-24-000605

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.